Medtronic (MDT) investor relations material

Market and portfolio performance

• Acute procedure volumes remain strong, with key franchises like Cardiac Rhythm Management and spine showing robust growth, supported by a favorable payer mix and strong free cash flow performance in challenging geographies.

• AI integration is enhancing both product capabilities and internal efficiencies, improving outcomes, workflow, and enabling monetization through stickier, higher-value offerings like StealthAXiS and GI Genius.

• Growth is driven by innovation across both new and established franchises, with a vitality index rising to the low-to-mid 20s, reflecting a higher proportion of revenue from recently launched products.

• Four generational growth drivers—cardiac ablation, renal denervation, Hugo robotics, and Altaviva pelvic health—are at different stages, each contributing to sustained top-line expansion.

• Neuroscience is expected to accelerate in the second half of the year, supported by recent acquisitions and a strong product pipeline.

Strategic investments and portfolio management

• Major investment in a soft tissue robot in China (Cornerstone) complements the Hugo platform, expanding customer choice and accelerating leadership in robotic surgery.

• Structural heart remains a profitable, growing segment with renewed investment in both inorganic (Anteris, Pi-Cardia) and organic programs, aiming for higher growth rates in coming years.

• Portfolio rationalization continues, with the recent MiniMed spin-out allowing focus on higher-return cardiovascular, MedSurg, and neuroscience segments, and ongoing SKU-level optimization.

• M&A activity has increased, with $2.7 billion spent over the past year on tuck-in acquisitions and ventures, targeting innovation acceleration without large-scale deals.

• Earnings dilution from acquisitions is managed through embedded guidance, leveraging gross margin improvements and reinvestment in innovation.

Operational improvements and outlook

• Operational enhancements, including Kaizen and design-to-cost strategies, are expected to drive margin expansion, aiming to return to pre-COVID gross margin levels.

• FY 2027 revenue guidance is underpinned by continued cardiovascular strength, accelerating neuroscience, and MedSurg momentum, with growth drivers providing additional runway.

• Capital allocation prioritizes dividends, increased M&A for growth, and a dual-track approach to innovation through both organic and inorganic initiatives.

• Sustained sales growth in the 6% range is supported by a stronger base and sequential generational growth drivers, with further details to be shared at the upcoming Investor Day.

• The company is focused on delivering both growth and leverage, aiming for sustainable EPS improvement.